- authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fed condition.
This study tests whether a generic version of mesalamine, a medicine for ulcerative colitis, behaves the same way in the body as an existing brand. Healthy adult volunteers will take a single capsule after eating a meal, and blood samples will track how the medicine is absorbed.
Romania - recruitingTherapeutic use (Phase IV)
Effect of Tofacitinib on coagulation and platelet function, and its role in thromboembolic events
This study looks at how medicines for ulcerative colitis, including tofacitinib and anti-TNF drugs, affect blood clotting. Researchers want to see how these treatments change platelets—the tiny cells that stop bleeding. They will also check how well the bowel heals after three months of treatment.
Spain - recruitingTherapeutic confirmatory (Phase III)
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
This study tests a new tablet version of mesalazine for people with mild to moderate ulcerative colitis. Researchers want to see if it is just as safe and effective as an established treatment at calming gut inflammation and helping symptoms settle down after eight weeks of daily treatment.
Spain · Slovakia · France - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.
This trial tests whether two different brands of mesalamine capsules work identically in the body. Mesalamine is a common medicine used to treat ulcerative colitis. Healthy adult volunteers will take single doses of each brand while fasting, allowing researchers to measure and compare how the medicine is absorbed.
Romania - authorisedTherapeutic use (Phase IV)
STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial
This clinical trial looks at whether adults with ulcerative colitis who are in deep remission can safely stop taking their JAK inhibitor tablets. Researchers want to see if pausing treatment keeps symptoms away, lowers side effect risks, and improves quality of life compared to staying on regular doses.
France - recruitingTherapeutic confirmatory (Phase III)
Evaluating the efficacy and safety of hyperbaric oxygen therapy as an adjuvant treatment compared to biologic therapy alone in moderate to severe ulcerative colitis in adults
This study is looking at a new way to treat severe ulcerative colitis. It tests if adding oxygen therapy to existing biologic medicines works better than biologics alone to reduce symptoms like diarrhoea and blood in your poo, and improve gut healing.
Poland - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis
Researchers are testing a new medicine called SOR102 for ulcerative colitis. This first study checks if it's safe in healthy people and those with the condition. It's an early step to see how SOR102 works in the body and if it could help patients in the future.
Bulgaria · Poland - recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
This study is looking at a medicine called Simponi for children and teenagers with a gut condition called ulcerative colitis. It wants to see if Simponi can help them feel better and heal their gut, and if it's safe to use.
Poland · France · Italy - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB310 in Patients with Active, Mild to Moderate Ulcerative Colitis (COMPOSER-1)
This study is looking into a new treatment called MB310 for people with ulcerative colitis. It's an early-stage trial checking if the treatment is safe, how well it settles in the body, and if it shows any early signs of helping patients with mild to moderate symptoms.
Austria · Poland · Bulgaria - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
This study is testing a new medicine, Ozanimod, for people in the UK with moderate to severe ulcerative colitis. It's looking at how well the medicine helps control symptoms and improve the gut, as well as checking for any side effects. It's a key stage of testing before being widely available.
Belgium · Romania · Poland - recruitingHuman Pharmacology (Phase I)- Other
Testing Insulin Enemas for Ulcerative Colitis: A First-Stage Clinical Trial
This study is looking at a new way to treat ulcerative colitis using insulin delivered as an enema. It's the very first time this treatment is being tested in people. The aim is to see if it's safe and how the body reacts to it.
Poland - recruitingTherapeutic use (Phase IV)
VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target
This study, called VERDICT, looks at how best to treat ulcerative colitis. It compares different treatment goals using Entyvio, a common medication. The main aim is to see which treatment approach helps patients avoid colitis-related problems for the longest time.
Italy · Belgium · France - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medicine called tulisokibart for people aged 18 and over with moderate to severe ulcerative colitis. It aims to see if the medicine is safe and helps to reduce symptoms like stomach pain and bleeding, compared to a dummy treatment.
Czechia · Poland · France - authorisedTherapeutic exploratory (Phase II)
T-FORE - Pilot study of a new technique of Oral Fecal Transplantation using frozen stool capsules for the maintenance treatment of pediatric Ulcerative Colitis (UC)
This study looks at a new way to treat Ulcerative Colitis in children using healthy gut bacteria from donor stool. They are testing both capsules and enemas to see which method works best to improve the gut’s natural balance over time.
France - recruitingHuman Pharmacology (Phase I)- Other
Study to evaluate food effect on the pharmacokinetics of mesalazine oral formulation in healthy volunteers.
This study is looking at how a common medicine for ulcerative colitis, called mesalazine, is absorbed by the body when taken with food. It involves healthy volunteers and aims to help us understand the best way to take this medication.
Spain - recruitingTherapeutic use (Phase IV)
A Prospective, Open-label Pilot Study to Evaluate Effector Mechanisms of Hyperbaric Oxygen Therapy in Patients with Moderate-to-Severe Ulcerative Colitis: The PARADOX study
This study, called PARADOX, investigates hyperbaric oxygen therapy (HBOT) for moderate-to-severe ulcerative colitis. Researchers want to understand how HBOT works at a very detailed level, looking at blood, gut lining, and gut bacteria to see if it helps reduce inflammation and symptoms.
Netherlands - recruitingPhase I and Phase II (Integrated)- Other
Adipose-derived mesenchymal stem cells as local treatment of ulcerative colitis
This study is looking at a new way to treat ulcerative colitis using special cells from fat tissue. Doctors want to see if injecting these cells into the inflamed area can help calm down the gut and reduce symptoms. It's an early-stage study to check safety and how well it works.
Denmark - recruitingTherapeutic use (Phase IV)
(A)nalysis of immunological (VA)riables in ex vivo (T)ofacitinib-treated human biopsies from (A)ctive ulcerative colitis patients to predict clinical (R)esponse (the AVATAR study).
This study looks at how a medicine called Xeljanz (tofacitinib) affects cells from people with ulcerative colitis. Researchers want to understand if these early changes can help predict which patients will get better with this treatment.
Italy - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fed condition.
This study compares two different brands of mesalamine capsules, a medicine for ulcerative colitis, in healthy adults. It checks if they work the same way in the body after a single dose, under fed conditions.
Romania - authorisedTherapeutic confirmatory (Phase III)
FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial
This study is comparing different medicines for ulcerative colitis. It aims to find out which new treatments work best to help people feel better and get their symptoms under control. We're looking at things like stopping bleeding and improving bowel habits over time.
France - recruitingPHASE3
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
This study is looking at a new medicine called filgotinib for children and teenagers aged 8 to 18 with moderate to severe ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, compared to what we already know about its use in adults.
Belgium · Croatia · France - recruitingPHASE3
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
This study is looking at a medicine called risankizumab for children and young people with ulcerative colitis (UC). It aims to see how well and safely it works, and how it moves through the body, for those aged 2 to 17 with moderate to severe UC.
United States · Belgium · Brazil - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis
This study is testing a new medicine called Rosnilimab for people with moderate to severe Ulcerative Colitis. Researchers want to see if it helps reduce symptoms and improve gut health compared to a dummy treatment, and if it's safe to use.
France · Germany · Austria - recruitingTherapeutic confirmatory (Phase III)
A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects with Ulcerative Colitis Who Completed the Study M11-290
This study looks at the long-term safety of a treatment called Humira for children and teens with ulcerative colitis. It's for those who have already been on Humira in a previous study. We want to see how well they continue to do.
Slovakia · Poland - recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE)
This study compares a new medicine (PB016) with an existing one (Entyvio®) for adults with moderate to severe ulcerative colitis. It looks at how well they work to reduce symptoms and keep people well, as well as their safety.
Czechia · Poland · Romania - recruitingTherapeutic exploratory (Phase II)
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis
This study is testing a new medicine, JNJ-77242113, for people in the UK with moderate to severe ulcerative colitis. We want to see if it helps reduce symptoms and if it's safe compared to a dummy pill.
Czechia · Spain · Poland - recruitingTherapeutic exploratory (Phase II)
Orismilast for the treatment of moderate to severe ulcerative colitis
This study is looking into a new medicine called Orismilast for people in the UK with moderate to severe ulcerative colitis. It's a Phase II trial, meaning it's still in the earlier stages of testing. Researchers want to see if the medicine can help people feel better by reducing symptoms.
Denmark - recruitingPhase III and phase IV (Integrated)
Unravelling intestinal fibrosis in ulcerative colitis: INTERACT study
This study, called INTERACT, is for people with ulcerative colitis. Researchers are looking at how certain changes in the body are linked to scarring in the gut. They are testing a special scan and looking at cell changes to understand and track this scarring, hoping to find better ways to treat it.
Netherlands - recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study with Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis
This study is testing a new medicine called NX-13 for people in the UK with moderate to severe ulcerative colitis. Researchers want to see if it helps reduce symptoms and is safe compared to a dummy pill.
Belgium · Poland · Italy - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study to Learn How Different Amounts and Forms of the Study Intervention Called PF-07899895 are Tolerated and Act in the Body of Healthy Adults
This study is looking at a new medicine called PF-07899895 to see how well healthy adults tolerate it and how it works in their bodies. This is the first time it's being given to people.
Belgium - recruitingPhase III
Study evaluating the efficacy of icotrokinra in ulcerative colitis
This study is testing a new medicine, icotrokinra, for ulcerative colitis (UC) in adults and teenagers. It aims to see if icotrokinra can help reduce UC symptoms and keep the disease under control by targeting inflammation.
United Kingdom · England · Scotland - recruitingTherapeutic exploratory (Phase II)
A single arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjects with moderate to severe ulcerative colitis.
This study is testing a new medicine called ABBV-668 for people with moderate to severe ulcerative colitis. Doctors want to see if it helps improve the lining of the bowel after 8 weeks and if it's safe to use. It's a key step in understanding if this medicine could help patients.
Belgium · France · Poland - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC.
This study is testing a new medicine called PF-07054894 for people with ulcerative colitis. It will check if the medicine is safe, how well it works, and how the body uses it, compared to a dummy pill.
Germany · Poland - recruitingPHASE3
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
This study is testing a new treatment called Duvakitug for people with moderate to severe Ulcerative Colitis. We want to see if it helps keep the condition under control and if it's safe to use over a long time. Half the participants will get the new medicine, and half will get a dummy treatment to compare.
United States · Argentina · Australia - active not recruiting
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
This study looks at how treatments for ulcerative colitis have changed over time and how they affect people's health. It's about understanding which treatments work best for long-term health in people with poorly controlled ulcerative colitis.
United Kingdom - active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
United States · Argentina · Australia - active not recruitingNA
Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care
This study looks at a new support program for young people with Crohn's or ulcerative colitis who are moving from children's to adult healthcare. It aims to make this move smoother and improve their health and well-being.
Canada - active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
United States · Argentina · Australia - active not recruitingPHASE3
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
This study is looking at a medicine called tofacitinib for children aged 2-17 with a bowel condition called ulcerative colitis. It aims to see how well it works, how safe it is, and how the body uses it, especially if other treatments haven't worked.
United States · Australia · Belgium - authorisedTherapeutic use (Phase IV)
Switching to Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Sustained Remission: A Multicenter Randomized Controlled Trial (IDEA).
This study compares two ways to manage ulcerative colitis in older patients who are feeling well: continuing their usual medicine (thiopurines) or switching to a different one (mesalazine). It checks which approach is better at keeping the condition stable.
Spain - recruiting
Pregnancy and Inflammatory Bowel Disease
This study looks at how inflammatory bowel disease (IBD) affects pregnancy and how pregnancy affects IBD. We're studying women with Crohn's disease or ulcerative colitis who have been pregnant, aiming to understand symptoms during pregnancy and after birth.
France - active not recruitingPHASE3
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
This study looks at the long-term safety of a medicine called filgotinib for adults with ulcerative colitis. It's for people who have already been in another filgotinib study. The main goal is to see if taking filgotinib over a longer time is safe.
United States · Argentina · Australia - recruitingPHASE3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
This study looks at combining two medicines, mirikizumab and tirzepatide, for adults with ulcerative colitis (UC) who are also overweight or obese. The goal is to see if this combination helps UC symptoms improve and also leads to significant weight loss.
United States · Austria · Belgium - recruitingPHASE4
Impact of Anti-TNF, Vedolizumab and Tofacitinib on Aortic Stiffness, Carotid Intima-media Thickness and Cardiovascular Risk of Patients With Ulcerative Colitis
This study looks at how certain medicines for ulcerative colitis affect your heart and blood vessels. Researchers want to see if drugs like anti-TNF, vedolizumab, and tofacitinib change things like blood vessel stiffness or thickness over time.
France - active not recruitingPHASE2
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
This study is looking into a new treatment called Rosnilimab for people in the UK with moderate to severe ulcerative colitis. It aims to see how safe and effective it is compared to a dummy treatment.
United States · Austria · Bulgaria - active not recruitingPHASE2
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
This study looks at a new medicine called lutikizumab for adults with moderate to severe ulcerative colitis. It aims to see if it's safe and how well it works compared to a common treatment called adalimumab.
United States · Australia · Austria - recruiting
Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study
This study looks at using robotic surgery for inflammatory bowel disease (IBD) like Crohn's disease and ulcerative colitis. Researchers want to see if robots can help surgeons operate more effectively and how this new method compares to traditional keyhole surgery for IBD.
United Kingdom - recruitingPHASE4
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
This study looks at combining two medicines, vedolizumab and tofacitinib, for adults with moderate to severe ulcerative colitis. We want to see if this combination helps more than vedolizumab alone, especially for people who haven't responded well to other treatments.
United States · Canada - authorisedTherapeutic exploratory (Phase II)
The efficacy of oral vancomycin therapy in managing different phenotypes of paediatric inflammatory bowel diseases by correlating treatment response to commensal microbiota composition and function (VERDA)
This study looks at how a medicine called vancomycin helps children with ulcerative colitis. Researchers want to see if it makes children better and how it affects the gut's tiny living things (microbes) to help discover new treatment options for children with this condition.
Finland - recruitingNA
Personalized Anti-Inflammatory Fibres in Ulcerative Colitis
This study looks into how special fibre supplements, acacia gum and microcrystalline cellulose, affect inflammation in people with ulcerative colitis. Researchers want to see if these fibres can help reduce gut inflammation compared to a dummy treatment.
Canada